{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The identification of a novel mutation (E46K) suggests that Glu residues in the KTKEGV-type repeats regulate ␣-synuclein polymerization into amyloid fibrils. Aberrant polymerization leads to pathological inclusions and disease.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines the disease mechanism as aberrant ␣-synuclein polymerization into amyloid fibrils, directly linking functional assays to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The E46K mutation increased the propensity of ␣-synuclein to form amyloid fibrils. The effect was compared to A53T, a known pathogenic mutation.",
          "judgment": "Yes",
          "reasoning": "In vitro polymerization assays are standard for studying ␣-synuclein aggregation, directly modeling the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of assays",
          "extracted_paper_info": "The paper does not explicitly describe controls or replicates for the E46K mutation.",
          "judgment": "No",
          "reasoning": "No mention of wild-type controls or statistical replicates in the provided text. Proceeding to Step 3b."
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "The polymerization assay is a standard method in ␣-synuclein research for assessing amyloid formation.",
          "judgment": "Yes",
          "reasoning": "The assay is broadly accepted in the field for studying ␣-synuclein aggregation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The E46K mutation increases fibrillization propensity, but the effect is less than A53T. No statistical analysis or OddsPath calculation is provided.",
          "judgment": "No",
          "reasoning": "No statistical analysis or OddsPath calculation is reported. Proceeding to Step 4b."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study compares E46K to A53T (a known pathogenic mutation) but does not specify the number of control variants.",
          "judgment": "Max PS3_supporting",
          "reasoning": "The study uses at least two variants (E46K and A53T) for comparison, but the total number of controls is likely <11 based on the text."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "A",
          "position": "46"
        },
        "variant_string_id": "SNCA E46A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The substitution of Glu 46 for Ala increases ␣-synuclein assembly into amyloid fibrils.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism of abnormal polymerization is directly addressed."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The E46A mutation is tested for effects on fibrillization and amyloid ultrastructure.",
          "judgment": "Yes",
          "reasoning": "The polymerization assay is standard for studying ␣-synuclein aggregation."
        },
        {
          "step_name": "Step 3: Evaluate validity of assays",
          "extracted_paper_info": "No explicit description of controls or replicates for E46A.",
          "judgment": "No",
          "reasoning": "Proceeding to Step 3b."
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "The polymerization assay is broadly accepted in the field.",
          "judgment": "Yes",
          "reasoning": "The method is standard for ␣-synuclein aggregation studies."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analysis or OddsPath calculation is provided.",
          "judgment": "No",
          "reasoning": "Proceeding to Step 4b."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study compares E46A to wild-type and other variants but does not specify the number of controls.",
          "judgment": "Max PS3_supporting",
          "reasoning": "Likely <11 control variants used based on the text."
        }
      ],
      "final_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "83"
        },
        "variant_string_id": "SNCA E83K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The mutation of Glu 83 to Lys increases ␣-synuclein polymerization into amyloid fibrils.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism of abnormal polymerization is directly addressed."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The E83K mutation is tested for effects on fibrillization and amyloid properties.",
          "judgment": "Yes",
          "reasoning": "The polymerization assay is standard for studying ␣-synuclein aggregation."
        },
        {
          "step_name": "Step 3: Evaluate validity of assays",
          "extracted_paper_info": "No explicit description of controls or replicates for E83K.",
          "judgment": "No",
          "reasoning": "Proceeding to Step 3b."
        },
        {
          "step_name": "Step 3b: Accepted/validated assay",
          "extracted_paper_info": "The polymerization assay is broadly accepted in the field.",
          "judgment": "Yes",
          "reasoning": "The method is standard for ␣-synuclein aggregation studies."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No statistical analysis or OddsPath calculation is provided.",
          "judgment": "No",
          "reasoning": "Proceeding to Step 4b."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study compares E83K to wild-type and other variants but does not specify the number of controls.",
          "judgment": "Max PS3_supporting",
          "reasoning": "Likely <11 control variants used based on the text."
        }
      ],
      "final_strength": "PS3_supporting"
    }
  ]
}